K013462

JAN 11 2002

for this marketed device upon request by

interested persons.

510(k) SUMMARY

Hydrofera Bacteriostatic Wound Dressing A. Device Proprietary Name: Wound dressing external use Device Common Name: Hydrofera Bacteriostatic Wound Dressings are Description: blue in color and manufactured from a pure white synthetic material with absorbent spongelike characteristics. The two pigments have been added to render the material bacteriostatic. Please see Instructions for Use 1225532 B. Establishment Registration Number: Hydrofera LLC Establishment Name & Address: 322 Main Street Willimantic CT 06226 Unclassified C. Device Classification of Category: None D. Performance standards: Draft Labeling is attached E. Proposed Labeling: The subject wound dressing have the same F. Substantial Equivalence: intended use as the predicate device: Ultrafera wound dressing(K964614) and Hydrofera Bacteriostatic Nasal Dressing (K983276) Hydrofera Bacteriostatic Wound Dressings G. Materials: are comprised of absorbent polyvinyl alcohol PVA, free formaldehyde <5 ppm)Methylene Blue(less than or equal to 0.00025 gr/gr) and Crystal Violet (less than or equal to 0.00025 gr/gr)Hydrofera Bacteriostatic Wound Dressings H. Sterility: will be sterilized by either gamma or electron beam radiation to an SAL 10-6. The process will be followed in accordance with Method I Bioburden and validated with subsequent quarterly dose audits. Each Hydrofera Bacteriostatic Wound I. Packaging: Dressing will be individually packaged in a Mylar to Poly Tyvek (chevron) pouch. Hydrofera LLC certifies that safety and J. S & E Summary: effectiveness information will be provided



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 11 2002

Heather H. Bond
Director Polymer Technology
Hydrofera, LLC.
322 Main Street
Willimantic, Connecticut 06226

Re: K013462

Trade Name: Hydrofera Bacteriostatic Wound Dressing

Regulation Name: Dressing Regulatory Class: Unclassified

Product Code: FRO
Dated: October 15, 2001
Received: October 18, 2001

Dear Ms. Bond:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Heather Bond

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Neil R.P. Ogden Celia M. Witten, Ph.D., M.D. For

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Over-The-Counter-Use_

(Optional Format 1-2-96)

K013462 510(k) NUMBER (IF KNOWN): DEVICE NAME: HYDROFERA BACTERIOSTATIC WOUND DRESSING INDICATIONS FOR USE: Hydrofera Bacteriostatic Wound Dressings are intended as external dressings for use in local management of wounds such as pressure ulcers, donor sites, venous stasis ulcers, arterial ulcers, disbetic ulcers, abrasions, lacerations, and superficial bi post-surgical incisions, and other external wounds inflicted by trauma. (Division Sign-Off) Division of General, Restorative and Neurological Devices K013462 510(k) Number. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED.) Concurrence of CDRH, Office of Device Evaluation (ODE)

OR

Prescription Use

(Per 21 CFR 801.109)